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Abstract An economic analysis of data from a large-scale international survey, Confronting COPD in North America and 
Europe, was conducted in seven countries (Canada, France, Italy, the Netherlands, Spain, the U.K. and the U.S.A.), to 
investigate the burden of chronic obstructive pulmonary disease (COPD).The results demonstrated the high economic 
impact of COPD on the healthcare system and society in each country.The mean annual direct costs of the disease were 
particularly high in the U.S.A. (US$41 I9 per patient) and Spain (US$3 196 per patient) but relatively low in the 
Netherlands (US$606) and France (US$522). Lost productivity due to COPD had a particularly high impact on the 
economy in France, the Netherlands and the U.K., accounting for 67%, 50% and 4 I %  of overall costs, respectively.The total 
societal cost of COPD per patient ranged from over US$5646 in the U.S.A. to US$ IO23 in the Netherlands. 
In five out of seven countries, the majority (52-84%) of direct costs associated with COPD were due to inpatient 
hospitalizations. As acute exacerbations of COPD are a key driver of secondary care costs, interventions aimed at 
preventing and treating exacerbations effectively could significantly reduce the economic impact of this disease. In all of 
the participating counties, COPD was underdiagnosed and undertreated. Between 9% and 30% of patients were 
undiagnosed despite having symptoms consistent with COPD, and up to 65% of patients did not receive regular prescribed 
medication. Patients reported poor symptom control and considerable use of healthcare resources.Therefore, reducing 
the burden of COPD will involve better evaluation and diagnosis of patients with COPD, as well as improved management 
of chronic COPD symptoms by healthcare professionals.The survey also demonstrated that the societal costs of COPD 
were 4-l 7 times higher in patients with severe COPD than in patients with mild COPD. Patients with comorbid 
conditions (accounting for 30-57% of patients in each country) were also particularly costly to society.These results 
suggest that a high priority should be given to interventions aimed at delaying the progression of disease, preventing 
exacerbations and reducing the risk of comorbidities, in order to alleviate the clinical and economic burden of COPD in 
North America and Europe. 
0 2003 Elsevler hence Ltd 
INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) is a 
disease state characterized by progressive airflow 
limitation that is not fully reversible.The most important 
cause of COPD is a long-term smoking history (I).The 
global prevalence of COPD has been estimated at 
9.3 per IO00 males and 7.3 per IO00 females (all ages) 
(Z).These rates are likely to rise in the future, due to the 
long-term impact of increased smoking behaviour over 
recent decades, and population aging (3). Morbidity and 
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mortality from COPD are considerable, and increasing: 
by the year 2020, COPD is predicted to become the 
third leading cause of death and the sixth leading cause 
of disability worldwide (2). Society has to bear the 
economic impact of COPD, resulting from the direct 
costs of healthcare resource utilization and the indirect 
costs of lost productivity (4). 
Although the burden of COPD is considerable, the 
disease appears to be poorly recognized by patients and 
sub-optimally managed by physicians and healthcare 
decision makers (4). Consequently, patients may fail to 
seek healthcare when experiencing symptoms, and when 
they do seek contact with healthcare professionals, the 
condition is often underdiagnosed and undertreated. 
COPD is also underfunded in comparison with other 
serious and chronic conditions, particularly given the 
morbidity and mortality associated with this disease (4). 
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Reducing the burden of COPD may necessitate raised 
awareness about the impact of this disease on the 
patient, the healthcare system and the economy. 
To date, few studies have attempted to quantify the 
impact of COPD in individual countries. Yet obtaining 
information on the country-specific impact of COPD is 
important not only for increasing the recognition of 
COPD as a major health problem, but also for identifying 
effective interventions that may be targeted to reduce 
the burden of the disease on the patient and society 
overall. In an attempt to fill gaps in current knowledge, a 
large-scale international survey, Confronting COPD in 
North America and Europe, was conducted in eight 
countries (Canada, France, Germany, Italy, the 
Netherlands, Spain, the U.K. and the U.S.A.). This 
summary paper presents data on healthcare resource 
utilization, patient work loss, and associated direct and 
indirect costs due to COPD in the seven countries that 
participated in the economic analysis of the survey 
results. Issues relating to the differential management and 
burden of COPD between countries are discussed. 
Detailed results for each country participating in the 
survey are presented elsewhere (5-l I). 
METHODS 
The methodology for the Confronting COPD survey has 
been described in detail (12-I 3). Briefly, telephone 
interviews were conducted with 3265 patients and 905 
physicians to assess the impact of COPD on clinical 
outcomes, the healthcare system and the economy 
Patients included in the survey had been diagnosed with 
COPD, chronic bronchitis or emphysema, or had 
symptoms consistent with chronic bronchitis (persistent 
coughing with phlegm production for the last 2 years or 
more). In addition to clinical outcomes, patient responses 
were used to derive measures of healthcare resource 
utilization (including inpatient hospitalizations, emergency 
room visits, contacts with healthcare professionals, 
treatment and laboratory investigations), and lost 
productivity due to COPD. Local unit costs were applied 
to estimate the direct, indirect and total societal costs of 
COPD in seven of the eight participating countries 
(Canada, France, Italy, the Netherlands, Spain, the U.K. and 
the U.S.A.).A sub-analysis was conducted to investigate 
the relationships between the annual societal cost of 
COPD and disease severity, comorbidity, gender, smoking 
status and educational level in each of these countries. 
To compare the costs of COPD between countries, 
the Canadian and European results were converted to 
US dollars using 2002 exchange rates. A sensitivity 
analysis of total societal costs was also conducted, in 
which national currencies were converted into US 
dollars using Gross National Product (GNP) Purchasing 
Power Parities (PPPs) (I 997 values) instead of exchange 
rates (14). GNP PPPs are currency conversion rates that 
offer the advantage of equalizing the price of the same 
services in all countries (exchange rates tend to 
overestimate costs in relatively ‘rich’ countries and 
underestimate costs in relatively ‘poor’ countries) (I 5). 
RESULTS 
Patient demographics 
A summary of the demographics and clinical 
characteristics of the patients included in the 
Confronting COPD survey in each country are 
summarized in Table I .The mean age ranged from 6 l-66 
years, and 38-52% of patients were current smokers. 
There were considerable differences between samples in 
mean pack year smoking history, the percentage of 
patients diagnosed with COPD, and the percentage of 
patients diagnosed with other serious or chronic health 
conditions. The majority of patients in each country 
considered themselves to have mild or moderate COPD, 
and most patients believed that their condition was at 
least somewhat controlled with current medication. 
Healthcare resource utilization 
The results of the Confronting COPD survey revealed 
that the majority of patients in each country normally 
received care from their primary care practitioner (PCP) 
for this condition. The proportion of patients who 
contacted a PCP or specialist differed between countries 
(Fig. I). While only 13% of patients in the U.K. saw a 
specialist, this type of contact was reported by around 
two-fifths of patients in Spain, Italy, and the Netherlands. 
The frequency of contact with healthcare professionals 
is summarized in Table 2. The highest numbers of PCP 
visits was reported in the U.K. and the U.S.A. Patients in 
the U.S.A. also reported the most specialist visits, with a 
mean of 1.8visits per patient past year. In all countries, 
the majority of PCP and specialist visits were scheduled. 
The proportion of patients reporting unscheduled visits 
ranged from 6% in Italy to 22% in the U.K.An estimated 
4% of patients in each country had unscheduled specialist 
visits in the year prior to the survey (Fig. 2). Patients with 
COPD also reported inpatient hospitalizations and visits 
to the emergency room (ER) as a result of their 
condition in the past I2 months (Fig. 3). The Spanish 
survey sample reported the highest numbers of both 
inpatient stays and ER visits (Table 3). 
Medication use 
The survey results showed the proportion of patients in 
each country who received regular prescribed 
medication for COPD (Fig. 4).The pattern of prescribing 
varied between countries. Table 4 ranks each country 
according to the proportion of patients receiving the five 
most commonly prescribed drug classes (short-acting 
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FIGURE I. The percentage of patients reporting primary care practitioner (PCP) or specialist care in each country. 
P,-agonists, inhaled corticosteroids, anticholinergics, long- 
acting &-agonists and theophylline). Between I% and 8% 
of patients were treated with leukotriene receptor 
antagonists, and fewer than 6% of patients were treated 
with systemic corticosteroids. Non-steroidal anti- 
inflammatory drugs were received by up to 4% of patients. 
In addition to regular prescribed medicationthe survey 
assessed the percentage of patients who had received an 
influenza vaccination, antibiotics for the treatment of 
respiratory infection, or had used home oxygen therapy 
in the previous year (Fig. 5). The highest rates of 
antibiotic use were reported in the U.K. and the U.S.A. 
(57% and 54% of patients respectively). Only half (5 I %) 
of the patients in France had been vaccinated against 
influenza, compared with 7 I% of patients in the 
Netherlands. The percentage of patients reporting a 
requirement for home oxygen use ranged from 4% in the 
Netherlands to 26% in the U.S.A. 
Direct costs 
The annual direct cost of COPD per patient was 
calculated for each country participating in the 
Confronting COPD survey, and ranged from USS.522 in 
France to US$4 I I9 in the U.S.A. (Fig. 6). Although the 
breakdown of direct costs differed between countries, 
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FIGURE 2. Percentage of patients reporting scheduled and unscheduled contacts with healthcare professionals during the I2 months 
prior to the survey. 
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FIGURE 3. Percentage of patients reporting inpatient stays and ER visits during the I2 months prior to the survey. 
more than half of costs in Canada, Italy, Spain, the U.K. highest proportion of direct costs (25%), while in the 
and the U.S.A. resulted from inpatient hospitalizations Netherlands, almost half of direct costs (49%) were for 
(Fig. 7). In France, oxygen therapy accounted for the regular prescribed medication. 
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FIGURE 4. Percentage of patlents reporting treatment with regular prescrIptIon medication for COPD. 
Lost productivity in patients with COPD Societal costs 
The percentage of patients in the Confronting COPD The annual cost of lost productivity in patients with 
survey who were of working age ranged from 41% in COPD was calculated in each country, to provide an 
Spain to 82% in the U.S.A. (Table I). A number of estimate of the indirect cost of the disease. Indirect costs 
patients in the Confronting COPD survey reported that ranged from US947 per patient in the Italian survey 
they were completely prevented from working during sample (with a total of I58 days of work absence) to 
the previous year, were limited in the work they were US$ I527 per patient in the U.S.A. sample (6838 working 
able to do, or were absent from work as a result of their days lost).The estimated annual societal cost of COPD 
condition (Fig. 8). Patients in the U.S.A. reported greater per patient in each country is shown in Fig. 9.The direct 
productivity loss than any patients in any other country. cost of COPD was higher than the indirect cost of the 
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FIGURE 5. Use of antibiotics, influenza vaccination and home oxygen therapy during the previous year 
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FIGURE 6. Annual direct per patient costs of COPD it- each country. 
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FIGURE 7. Percentage breakdown of the annual direct per patient costs of COPD in each country. 
disease in all countries except France, where the cost of Sub-analysis of societal costs and patient 
patients’ work loss was almost double the cost of variables 
healthcare resource use due to COPD.The proportion 
of societal costs resulting from healthcare resource In each country, a sub-analysis of the total per patient 
utilization varied considerably between countries, from costs calculated from the Confronting COPD survey 
33% in France to 95% in Italy. revealed that patients who perceived themselves to have 
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FIGURE 8. Percentage of patients reporting lost productivity due to COPD during the I2 months prior to the survey. 
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FIGURE 9. Annual societal per patient cost of COPD in each country. 
Country 
FIGURE IO. Total societal costs per patient by self-perceived severity of COPD 
severe COPD were considerably more costly to the 
healthcare system and the economy than patients with 
mild or moderate COPD (Fig. IO). Similar results were 
gained when disease severity was assessed according to 
patient score on the Medical Research Council 
Dyspnoea Scale (mild: O-2, moderate: 34, severe: 5) 
(5-1 l).Annual societal costs in all countries were also 
higher in patients who reported comorbidities than in 
patients who had not been diagnosed with other serious 
or chronic conditions (Fig. I I). 
The total societal costs of COPD were also assessed 
in terms of sex, smoking status and educational level 
(Table 5). The per patient cost of COPD was higher in 
males than in females in Italy, the Netherlands, Spain and 
the U.K., but higher in females than in males in the 
remaining countries. Former smokers were more costly 
to the healthcare system and the economy than current 
smokers in all countries except France. Patients who had 
no education beyond leaving school (i.e. no further or 
higher education) were associated with higher per 
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FIGURE I I. Annual societal costs in pattents with COPD who had comorbidity/no comorbidity. 
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FIGURE 12. Annual societal costs In each country using GNP PPPs to exchange local currency into US dollars. 
patient societal costs than more educated patients in 
Canada, France, the Netherlands, Spain and the U.S.A. 
Sensitivity analysis 
The sensitivity analysis converted local currency values 
into US dollars using between-country differences in 
GNP PPPs, rather than exchange rates.This increased the 
per patient cost of COPD in all countries outside the 
U.S.A., as shown in Fig. 12. Patients in Spain were now 
associated with the highest per patient costs of COPD, 
followed by the U.S.A. and Canada. The Netherlands 
continued to have the lowest per patient cost. 
DISCUSSION 
The Confronting COPD survey provided a picture of the 
healthcare resource utilization and lost productivity due 
to COPD in patients from eight countries in North 
America and Europe.The survey included patients with 
physician-diagnosed COPD, chronic bronchitis and 
emphysema and those with undiagnosed chronic 
bronchitis, as defined by persistent cough with sputum 
production for at least 2 years. Direct, indirect and total 
societal costs were calculated from the survey data. 
The results demonstrated the high economic burden 
placed by COPD on the healthcare system and society in 
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each country.The mean annual direct costs of the disease 
were high in the U.S.A. (US$41 19 per patient) and Spain 
(US$3 I96 per patient), with relatively low costs in the 
Netherlands (US$606) and France (US$522). Lost 
productivity due to COPD had a particularly high impact 
on the economy in France, the Netherlands and the U.K., 
accounting for 67%, 50% and 41% of overall costs, 
respectively.The total societal cost of COPD per patient 
ranged from over US$5646 in the U.S.A. to US$lO23 in 
the Netherlands. 
Organization of COPD care 
In each country, more than half of patients in the survey 
were under the care of a primary care practitioner for 
the management of their condition, and up to two-fifths 
of patients were seeing a specialist. Although the 
majority of contacts with healthcare professionals were 
scheduled, a number of patients in each country required 
unscheduled emergency care for COPD, including visits 
to the hospital emergency room. This suggests that 
although patients were visiting a professional for 
treatment, many patients were experiencing poor 
symptom management. Indeed, 26%-65% of patients in 
the individual countries reported that their symptoms 
were only somewhat controlled, poorly controlled or 
not at all controlled.The highest rates of poor symptom 
control were reported in the U.S.A., which also had the 
highest per patient costs of COPD. These results may 
suggest that reducing the impact of COPD on the 
healthcare system and society is likely to require 
improvements in the management of chronic symptoms. 
Diagnosis and treatment 
The Confronting COPD survey provided insights into 
the reasons for the sub-optimal management of COPD 
in North America and Europe. Many patients with COPD 
in the participating countries remained undiagnosed 
(ranging from 9% of patients in the U.S.A. to 30% of 
patients in the U.K.). Underdiagnosis may be partly due 
to the underutilization of spirometry (recommended by 
treatment guidelines to confirm diagnosis) (I): only 45% 
of patients in the Confronting COPD survey reported 
that their lung function had been assessed using this 
method (I 3). The under-recognition of early symptoms 
of the disease by patients (particularly smokers, who may 
fail to appreciate the significance of chronic cough and 
sputum production) may also be a contributory factor 
(16). 
The underdiagnosis of COPD is likely to represent a 
barrier to optimal management, as patients without a 
diagnosis may be less likely than diagnosed patients to 
receive regular prescribed medication. However, in each 
country, the proportion of patients who were not 
receiving regular medication exceeded the number of 
patients without a diagnosis, suggesting that under- 
treatment may also be a factor in patients who have been 
diagnosed with COPD. The smallest discrepancy 
between the proportion of patients diagnosed and 
treated for COPD was observed in the Netherlands 
(81% and 73% of patients, respectively). Dutch patients 
reported the highest levels of symptom control (with 
72% of patients reporting that their condition was well- 
controlled or completely controlled), some of the lowest 
rates of hospitalizations, emergency room visits, and 
unscheduled contacts with healthcare professionals, and 
lower per patient societal costs than patients in any 
other country. Although relatively low differences 
between the percentage of patients diagnosed and 
treated were also seen in Canada and Spain (difference 
of 12%) the proportion of patients reporting good or 
optimal symptom control was much lower than in the 
Netherlands (60% in each country), and the direct and 
societal costs of COPD were considerably higher.These 
results suggest that even when the majority of diagnosed 
patients are receiving treatment for COPD, sub-optimal 
management remains a significant problem, with 
associated healthcare resource utilization and lost 
productivity. 
Looking at patients who received regular prescribed 
medication for COPD in more detail, the results of the 
Confronting COPD survey suggested that prescription 
patterns differed considerably between countries. This 
may reflect uncertainty among healthcare professionals 
about which medications are most effective for the 
treatment of this disease. Indeed, physicians who were 
questioned as part of the Confronting COPD survey 
revealed a need for further education on the effective- 
ness of varying approaches to COPD management (I 3). 
Uncertainty surrounding the optimal choice of 
interventions exists despite the recent publication of 
international consensus guidelines for COPD, which 
recommend bronchodilators as the mainstay of therapy 
for COPD, with consideration of inhaled corticosteroids 
in patients with moderate to severe COPD who suffer 
from frequent exacerbations (I). The undertreatment 
seen in the survey suggests that the implementation of 
guideline recommendations is limited in practice. 
Implementation of international guidelines may be 
limited by the availability of country-specific guidelines 
(e.g. in France, the Netherlands, the U.K. and the U.S.A.) 
with different recommendations. Other factors that may 
limit the impact of guidelines may include country- 
specific preferences among patients or physicians for 
particular drugs, resource limitations or budget 
constraints (17). Whatever the reasons for the 
differential treatment of COPD between countries, the 
uncertainty surrounding optimal management strategies 
is likely to result in inadequate disease control, thus 
contributing to the high costs of the disease to the 
healthcare system and society. 
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COPD hospitalization 
In Canada, Italy, Spain, the U.K. and the U.S.A., the 
majority (52-84%) of direct costs associated with COPD 
were due to inpatient hospitalizations. The only 
exceptions to the major role of hospitalization costs 
were France, where the main direct cost was due to 
oxygen therapy, and the Netherlands, where medication 
costs represented a major proportion (49%) of the 
relatively low cost of COPD to the healthcare system. 
One of the main causes of hospitalization in patients with 
COPD is acute exacerbations of the disease. Although 
the number of exacerbations was not directly assessed 
by the survey, the extent of antibiotic use reported 
during the previous year (ranging from 38% in the 
Netherlands to 57% in the U.K.) suggests that 
exacerbations caused by respiratory infection were a 
frequent occurrence. As acute exacerbations of COPD 
are a key driver of hospital costs (18) interventions 
aimed at preventing exacerbations may reduce the 
economic impact of the disease. International treatment 
guidelines recommend influenza vaccination for the 
prevention of respiratory infections (I), yet 29-60% of 
patients in each country had not been vaccinated in the 
previous year. It is interesting to note that the lowest 
hospitalization rates were observed in the Netherlands, 
where patients reported higher rates of influenza 
vaccination than in any other country. 
Medications that may reduce the rate and frequency of 
exacerbations by acting on underlying lung inflammation 
(which is triggered and worsened by infection) may also 
have a role to play in reducing the number of patients 
with COPD who require a hospital stay for the 
management of acute symptoms. There was some 
indication of a relationship between the use of 
medication in the survey and the rate of hospitalization. 
Patients in the Netherlands reported the lowest number 
of hospitalizations and the highest reported use of 
regular prescribed medication of any country in the 
survey. Almost half of the patients in the Netherlands 
received inhaled corticosteroids, and a quarter of 
patients were treated with long-acting &-agonists. In 
Spain, where the number of hospitalizations reported 
was particularly high, patients reported the lowest 
utilization of long-acting &-agonists of any country in the 
survey, and less than one-fifth of patients were treated 
with inhaled corticosteroids. 
Impact of patient characteristics on 
costs 
Patients with severe COPD may be more likely to suffer 
frequent exacerbations and poor symptom control than 
patients with mild or moderate COPD (I 8) resulting in 
substantial use of healthcare resources, lost productivity 
and associated direct and indirect costs.The substantial 
impact of patients with severe COPD was highlighted by 
the sub-analysis of costs from the Confronting COPD 
survey, which showed that the societal cost of severe 
COPD per patient was 4-l 7 times higher than the cost 
per patient with mild COPD. 
Consequently, interventions aimed at delaying the 
progression of disease could reduce the economic 
impact of COPD in North America and Europe.The only 
intervention known to reduce the progressive lung 
function decline in COPD is smoking cessation (I), which 
has been shown to lead to fairly rapid improvements in 
pulmonary function (I 9). However, smoking cessation is 
likely to be delayed if patients do not contact a 
healthcare professional for symptoms of COPD, and 
remain undiagnosed. Even when patients do succeed in 
quitting, the societal benefits of smoking cessation 
intervention are unlikely to be seen for a number of 
years, due to the long-term cumulative impact of tobacco 
smoking on patient health (20). 
In almost every country in the survey, former smokers 
were more costly to the healthcare system and the 
economy than current smokers.This may be due to the 
‘quitting ill’ effect, in which smokers quit upon developing 
disease symptoms or immediately after diagnosis of 
smoking-related diseases (2 I-22). Therefore, 
encouraging patients to stop smoking before they 
develop COPD, or preferably discouraging the general 
population from taking up tobacco smoking at all, are 
likely to be important strategies for reducing the future 
impact of this disease on society. 
In addition to delaying the progression to severe 
disease, smoking cessation may help to reduce the risk of 
comorbidity in patients with COPD.The importance of 
reducing comorbidity was demonstrated by the survey, 
which showed that in all countries, the combined direct 
and indirect per patient costs of COPD were 
considerably higher in patients with COPD and other 
serious or chronic health conditions than in patients with 
COPD alone, supporting the results of previous studies 
(23-24). 
Reasons for cost differences between 
countries 
Overall, the economic impact of COPD differed between 
countries in the Confronting COPD survey. Some of the 
inter-country variability in costs may have been due to 
local differences in unit costs for healthcare services and 
time lost from work.To test whether this was indeed the 
case, a sensitivity analysis used GNP PPPs (which 
equalize prices according to purchasing power) to 
convert local currency values into US dollars. This 
method of currency conversion increased the per 
patient societal cost of COPD in all countries outside 
the U.S.A., and Spain moved from second to first in the 
highest-lowest ranking of costs. However, the overall 
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pattern of cost differences between countries remained 
similar, suggesting that there are real differences between 
countries in the burden of COPD. 
The disparities in COPD costs between countries 
enrolled in the Confronting COPD survey may be due to 
between-country differences in the characteristics of the 
patients with COPD who were enrolled in the survey 
samples, or variability in the management of COPD by 
individual healthcare systems. Factors that may influence 
the economic impact of COPD may be highlighted by 
considering patient characteristics, management 
approaches and healthcare resource use in the countries 
with high (U.S.A. and Spain) and low direct and societal 
per patient costs (France, Italy and the Netherlands) 
(Table 6). High costs in the U.S.A. and Spain were 
associated with high rates of severe COPD, while low 
costs in Italy and the Netherlands were associated with 
low rates of severe disease. However, the direct and 
societal costs of COPD were also low in France, where 
the proportion of patients with severe disease was 
relatively high. In addition, there appeared to be little 
relationship between costs and the percentage of 
patients reporting comorbidity (high in the U.S.A. and 
France, but low in Spain, Italy and the Netherlands). 
These results suggest that reasons other than between- 
country differences in patient characteristics (i.e. 
variability in COPD management) must contribute to the 
observed differences in costs. Patients in Spain and the 
U.S.A. reported a relatively low use of long-acting 
&-agonists, with a high requirement for inpatient 
hospitalization and emergency room visits. In contrast, 
low direct and societal costs in Italy, the Netherlands and 
France were associated with relatively high use of long- 
acting &-agonists, and low rates of hospitalization and 
emergency room care for COPD.Although further work 
is required to clarify the association between 
management strategies and COPD costs at a population 
level, these results suggest that long-acting &agonists 
may have a role to play in reducing the burden of COPD. 
Previous studies have shown that treatment with long- 
acting &-agonists reduces healthcare costs in patients 
with this disease (23-24). 
CONCLUSION 
The results of the Confronting COPD survey showed 
that COPD places a high economic burden on the 
healthcare system and society in all countries studied, 
with a particularly pronounced impact in Spain and the 
U.S.A. Reducing the burden of this disease in North 
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America and Europe will necessitate improvements to 
diagnosis rates, the management of chronic symptoms by 
healthcare professionals, the prevention and treatment of 
acute exacerbations, and the employment of 
interventions aimed at delaying the progression of 
disease, preventing exacerbations and reducing the risk 
of comorbidities in patients with COPD. 
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